Development of Abtids as A New Class of Anti-Infective Biologicals

Introduction

 

The project aims to develop a new class of biologic antimicrobials called AbTids and their cocktail based on bacteria specific camelid heavy chain antibodies to specifically target Antimicrobial resistance (AMR)

 

Stage of Development

 

Proof of concept

 

Unique Features of The Product/Technology

 

A new class of antibacterial biologics consisting of a toxic cationic antimicrobial peptide

combined to an anionic single chain antibody linked by a cleavable peptide and will be activated only on latching to the target and freeing of the peptide from the complex to lyse the target bacteria

 

Market Potential

 

The world anti-bacterial market is around USD $ 30 billion, with very less number of products to tackle drug resistant bacteria. The burn applications has a market size of around USD $ 60 million

 

Plans to Take Innovation

 

Once the POC is developed, collaborations with established pharma players for taking the molecules to the clinic.

 

For further information please contact

 

Biotechnology Industry Research Assistance Council (BIRAC)

1 st Floor, MTNL Building, 9, CGO Complex,

Lodhi Road, New Delhi- 110003

Phone: +91-11-24389600

Email- birac.dbt@nic.in